Cipla Announces Massive Reduction in Prices of Anti-Cancer Drugs

by Kathy Jones on  May 4, 2012 at 7:49 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

Indian pharmaceutical firm Cipla has announced a massive 76 percent price cut for some of its cancer drugs that are used to treat lung, brain and kidney cancers.
 Cipla Announces Massive Reduction in Prices of Anti-Cancer Drugs
Cipla Announces Massive Reduction in Prices of Anti-Cancer Drugs

The decision comes just two months after the Patent Office in the country allowed Natco to manufacture generic version of Bayer's Nexavar drug that was exclusively used to treat advanced kidney cancer.

Cipla has announced that a month's dose of its generic drug, Soranib, will now be available for just Rs 6,840 instead of more than Rs 28,000 while it has also reduced prices of its lung cancer drug Gestinib and a brain tumor drug Temozolomide.

Cipla chairman Y K Hamied said that the decision was taken as part of a humanitarian approach by the company and added that it will help relieve the financial burden on the patients. "This initiative of price reduction is a humanitarian approach by Cipla to support cancer patients. Drugs constitute a significant proportion of the overall cost of cancer treatment and reduction in costs can greatly relieve the burden", he said.


Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Top 10 Health Benefits of Cloves 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive